The Tigard, Oregon-based biopharmaceutical company focuses on developing therapeutics for autoimmune diseases, including multiple sclerosis, celiac disease, type 1 diabetes, rheumatoid arthritis, uveitis, stroke, optic neuritis, and other diseases. Its lead compound, RTL1000, is designed to treat multiple sclerosis, and the company's biological platform drugs target the CD74 receptor on monocytes to treat neuroinflammatory and degenerative diseases, such as optic neuritis, methamphetamine addiction, and stroke.